The year 2014 has been a fairly good one for Johnson & Johnson. The company’s stock gradually gained 10% on the back of its growing pharmaceutical business. Additionally, the divestitures of flat or declining businesses showcased J&J’s commitment to increasing shareholder value. Overall, the company went through a significant transformation as far as its image is concerned, and is now being seen as pharma-centric as opposed to medical devices focused. Its existing and new drugs saw good adoption both in the U.S. and international markets. In this note, we’ll review key developments that shaped Johnson & Johnson’s business in 2014 and will follow it up with another note shortly in the future discussing what 2015 holds for the company.
Hey, check out all the research scientist jobs. Post your resume today!
